View Older Stories View More Recent Stories

Sep 29, 2022 07:00AM Zynerba Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference
Sep 22, 2022 07:00AM Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
Sep 22, 2022 07:00AM Zynerba Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare Conference
Sep 8, 2022 09:15AM Zynerba Pharma (ZYNE) Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium
Sep 8, 2022 09:15AM Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium
Sep 8, 2022 09:15AM Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium
Sep 6, 2022 07:00AM Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference
Sep 6, 2022 07:00AM Zynerba Pharmaceuticals to Present In-Person at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 31, 2022 07:00AM Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium
Aug 31, 2022 07:00AM Zynerba Pharmaceuticals Announces Oral Presentation at The Society for the Study of Behavioural Phenotypes (SSBP) 24th International Research Symposium
Aug 10, 2022 07:00AM Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
Aug 10, 2022 07:00AM Zynerba Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Highlights
Aug 3, 2022 07:00AM Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference
Aug 3, 2022 07:00AM Zynerba Pharmaceuticals to Present In Person at the Canaccord Genuity 42nd Annual Growth Conference
Jul 21, 2022 07:07AM Zynerba Pharma (ZYNE) Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
Jul 21, 2022 07:00AM Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
Jul 21, 2022 07:00AM Zynerba Pharmaceuticals Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park Capital
Jul 7, 2022 07:00AM Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference
Jul 7, 2022 07:00AM Zynerba Pharmaceuticals Announces Panel Presentation and Poster Presentations at the NFXF International Fragile X Conference
Jun 22, 2022 05:55AM Zynerba Pharma (ZYNE) Reports Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel
Jun 21, 2022 08:05PM Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome
Jun 21, 2022 08:05PM Zynerba Pharmaceuticals Announces Positive Top Line Results from Open-Label Phase 2 INSPIRE Trial of Zygel™ in 22q11.2 Deletion Syndrome
Jun 1, 2022 07:00AM Zynerba Pharmaceuticals Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting
Jun 1, 2022 07:00AM Zynerba Pharmaceuticals Presents Data on Zygel™ at the American Society of Clinical Psychopharmacology Annual Meeting
May 24, 2022 07:00AM Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
May 24, 2022 07:00AM Zynerba Pharmaceuticals Announces Podium and Poster Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
May 17, 2022 07:00AM Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
May 17, 2022 07:00AM Zynerba Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
May 16, 2022 07:00AM Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
May 16, 2022 07:00AM Zynerba Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Highlights
May 11, 2022 01:30PM Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meetin
May 11, 2022 01:30PM Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the International Society for Autism Research Annual Meetin
May 9, 2022 04:57PM Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting
May 9, 2022 04:57PM Zynerba Pharmaceuticals Announces Podium Presentation at the International Society for Autism Research Annual Meeting
May 2, 2022 07:03AM Zynerba Pharma (ZYNE) Reports Long-Term Safety and Efficacy Data of Zygel
May 2, 2022 07:00AM Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting
May 2, 2022 07:00AM Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting
Apr 21, 2022 07:00AM Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting
Apr 21, 2022 07:00AM Zynerba Pharmaceuticals Announces Presentation of Poster at the 2022 Society of Biological Psychiatry Annual Meeting
Apr 5, 2022 07:00AM Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
Apr 5, 2022 07:00AM Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference
Mar 22, 2022 07:00AM Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit
Mar 22, 2022 07:00AM Zynerba Pharmaceuticals to Participate in the Cantor Rare Orphan Disease Summit
Mar 1, 2022 06:00AM Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
Mar 1, 2022 06:00AM Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
Feb 28, 2022 04:05PM Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome
Feb 28, 2022 04:05PM Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome
Feb 28, 2022 07:00AM Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome
Feb 28, 2022 07:00AM Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome
Feb 15, 2022 07:00AM Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer
View More Recent Stories View Older Stories